Clinical trials

This is a Phase I study to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in adult patients with recurrent glioblastoma.

Investigator

Ashley Ghiaseddin

Ages

18 Years - 80 Years

Sexes

All

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as…

Investigator

Christopher Harden

Ages

40 Years - N/A

Sexes

All